Acumen Pharmaceuticals Statistics
Share Statistics
Acumen Pharmaceuticals has 60.08M shares outstanding. The number of shares has increased by 3.82% in one year.
| Shares Outstanding | 60.08M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 45.03M |
| Failed to Deliver (FTD) Shares | 805 |
| FTD / Avg. Volume | 0.38% |
Short Selling Information
The latest short interest is 1.45M, so 2.41% of the outstanding shares have been sold short.
| Short Interest | 1.45M |
| Short % of Shares Out | 2.41% |
| Short % of Float | 3.21% |
| Short Ratio (days to cover) | 7.19 |
Valuation Ratios
The PE ratio is -3.56 and the forward PE ratio is -1.75.
| PE Ratio | -3.56 |
| Forward PE | -1.75 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 0.7 |
| P/FCF Ratio | -4.32 |
| PEG Ratio | n/a |
Enterprise Valuation
Acumen Pharmaceuticals Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 19.01, with a Debt / Equity ratio of 0.11.
| Current Ratio | 19.01 |
| Quick Ratio | 19.01 |
| Debt / Equity | 0.11 |
| Total Debt / Capitalization | 9.55 |
| Cash Flow / Debt | -1.53 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.2% and return on capital (ROIC) is -20.69%.
| Return on Equity (ROE) | -0.2% |
| Return on Assets (ROA) | -0.17% |
| Return on Capital (ROIC) | -20.69% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.03M |
| Employee Count | 51 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -29.51% in the last 52 weeks. The beta is 0.04, so Acumen Pharmaceuticals 's price volatility has been higher than the market average.
| Beta | 0.04 |
| 52-Week Price Change | -29.51% |
| 50-Day Moving Average | 2.54 |
| 200-Day Moving Average | 2.98 |
| Relative Strength Index (RSI) | 36.51 |
| Average Volume (20 Days) | 214.13K |
Income Statement
In the last 12 months, Acumen Pharmaceuticals had revenue of $0 and earned -$52.37M in profits. Earnings per share was $-1.08.
| Revenue | 0 |
| Gross Profit | -42.32M |
| Operating Income | -61.14M |
| Net Income | -52.37M |
| EBITDA | -51.61M |
| EBIT | - |
| Earnings Per Share (EPS) | -1.08 |
Balance Sheet
The company has $66.89M in cash and $28.49M in debt, giving a net cash position of $38.40M.
| Cash & Cash Equivalents | 66.89M |
| Total Debt | 28.49M |
| Net Cash | 38.40M |
| Retained Earnings | -222.80M |
| Total Assets | 266.98M |
| Working Capital | 187.72M |
Cash Flow
In the last 12 months, operating cash flow was -$43.06M and capital expenditures -$21.00K, giving a free cash flow of -$43.09M.
| Operating Cash Flow | -43.06M |
| Capital Expenditures | -21.00K |
| Free Cash Flow | -43.09M |
| FCF Per Share | -0.89 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
ABOS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -53.2% |
| FCF Yield | -35.33% |
Analyst Forecast
The average price target for ABOS is $7, which is 244.8% higher than the current price. The consensus rating is "Buy".
| Price Target | $7 |
| Price Target Difference | 244.8% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
Scores
| Altman Z-Score | -0.1 |
| Piotroski F-Score | 2 |